These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 26883220)

  • 1. The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.
    Broomfield A; Jones SA; Hughes SM; Bigger BW
    J Inherit Metab Dis; 2016 Jul; 39(4):499-512. PubMed ID: 26883220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LSDs and the immune system.
    Beck M; Vanier M
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S85. PubMed ID: 20040317
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives from B cell immunology: fact and fancy.
    Hunt SV
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S86-99. PubMed ID: 20040318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
    Kishnani PS; Dickson PI; Muldowney L; Lee JJ; Rosenberg A; Abichandani R; Bluestone JA; Burton BK; Dewey M; Freitas A; Gavin D; Griebel D; Hogan M; Holland S; Tanpaiboon P; Turka LA; Utz JJ; Wang YM; Whitley CB; Kazi ZB; Pariser AR
    Mol Genet Metab; 2016 Feb; 117(2):66-83. PubMed ID: 26597321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enzyme replacement therapy of lysosomal storage diseases].
    Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
    Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
    Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.
    Wang J; Lozier J; Johnson G; Kirshner S; Verthelyi D; Pariser A; Shores E; Rosenberg A
    Nat Biotechnol; 2008 Aug; 26(8):901-8. PubMed ID: 18688246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement and enhancement therapies for lysosomal diseases.
    Desnick RJ
    J Inherit Metab Dis; 2004; 27(3):385-410. PubMed ID: 15190196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common antigenicity for two glycosidases.
    Kakavanos R; Lehn P; Callebaut I; Meikle PJ; Parkinson-Lawrence EJ; Hopwood JJ; Brooks DA
    FEBS Lett; 2006 Jan; 580(1):87-92. PubMed ID: 16359666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maximizing the therapeutic potential of enzyme replacement therapy for lysosomal storage diseases.
    Gieselmann V
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):707-8. PubMed ID: 19954707
    [No Abstract]   [Full Text] [Related]  

  • 18. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.